www.hendersonvillenews.com/apps/pbcs.dll/article?AID=/2 -
[Cached Version]
Published on: 3/23/2007
Last Visited: 3/23/2007
David Beshara, the chief pharmacy officer for Tennessee Medicaid, said the potential savings from a state,s participation in Eli Lilly,s prescription-management program for Zyprexa were unclear. (Christopher Berkey for The New York Times)
...
Lilly,s pitch in 2005 was, , ,we,ll fund this program if you put our product on the preferred-drug list,, , said David Beshara, chief pharmacy officer for Tennessee Medicaid.
Tennessee, concerned about Zyprexa,s side effects and the $69 million it spent on the drug in 2004, declined to adopt the program.
Mr. Beshara said the potential savings from the program were unclear.And he cited another concern: the program has been offered in lieu of rebates that companies often pay to states that place their drugs on preferred lists.